Abstract

Major prognostic factors of endometrial cancer include stage, age, histopathological type, grading, depth of invasion of myometrium, and presence of Lymph-vascular Space Invasion (LVSI). This study evaluated the LVSI in disease free survival (DFS) and overall survival (OS) in high-risk endometrial cancer endometrioid type. This was a retrospective study. Survival analysis using Kaplan-Maier curve, log rank test, cox-regression and logistic regression were used to determine effects among variables. Among fifty-six patients, 43% of patients were <60 years, 73% with BMI <30, 17% were multiparous, and 79% were menopausal patients. There were 32% of patients with positive LVSI. Most clinical stages were found in stage III with 31 cases (55%). Patients with positive LVSI had OS lower than patients with negative LVSI (50% vs 55.3%). There were no significant results of LVSI as prognostic factor for OS. Patients with LVSI positive had survival time of 26.5 months (20.5 – 32.5). There were no significant results of LVSI as prognostic factor for DFS. Patients with positive LVSI had lower DFS than patients with negative LVSI (81.8% vs 85.7%). There were significant results of LVSI as prognostic factor for high-risk endometrioid type endometrial cancer with stage endometrial cancer with p = 0.01. LVSI acts as prognostic factor for high-risk endometrioid type endometrial cancer associated with stage endometrial cancer. However, there was no effect in DFS and OS.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.